[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gallbladder-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gallbladder-diseases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,87,112,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641557","endoscopic-vs-non-endoscopic-drainage-for-benign-gallbladder-diseases-in-high-risk-patients-or-patients-desiring-gallbladder-preservation-100641557",false,"NCT07649811","Endoscopic vs Non-endoscopic Drainage for Benign Gallbladder Diseases in High-risk Patients or Patients Desiring Gallbladder Preservation","Efficacy and Safety Evaluation of Endoscopic Treatment for Benign Gallbladder Diseases: A Multicenter Prospective Cohort Study","GB-PRESERVE","Inclusion Criteria:\n\n* Age ≥ 18 years, and voluntarily signed the informed consent form;\n* Radiologically confirmed symptomatic benign gallbladder disease (symptomatic gallbladder stones, gallbladder polyps meeting surgical indications, acute cholecystitis TG18 Grade I\u002FII); and meeting any of the following specific population criteria:\n\n  1. High-risk surgical patients: ASA classification ≥ III, or presence of severe comorbidities that significantly increase the risk of laparoscopic cholecystectomy (LC);\n  2. Patients with concomitant common bile duct stones (CBDS) and a strong desire for gallbladder preservation: presence of CBDS confirmed by MRCP\u002FERCP examination, and still strongly requesting the preservation of gallbladder function after being fully informed.\n\nExclusion Criteria:\n\n* Suspected or confirmed gallbladder malignancy;\n* Complications requiring emergency surgical intervention (gangrene, perforation, diffuse peritonitis);\n* Uncorrectable severe coagulation dysfunction;\n* Presence of severe anatomical deformity or obstruction of the stomach, duodenum, or esophagus, where the endoscope is expected to be unable to reach the target site (papilla or pericholecystic area);\n* Significant gallbladder atrophy (longitudinal diameter \\\u003C 4 cm or anteroposterior diameter \\\u003C 2 cm);\n* Pregnant or lactating women;\n* Previous history of cholecystectomy;\n* Presence of psychiatric disorders or any condition that prevents cooperation with treatment and follow-up;\n* Unwilling or unable to sign the informed consent form.","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","OBSERVATIONAL","Common gallbladder conditions like gallstones, polyps, and gallbladder inflammation are typically treated by surgically removing the gallbladder. However, surgery may be too risky for elderly patients or those with severe medical conditions, and some patients strongly prefer to keep their gallbladder.\n\nNewer, less-invasive endoscopic treatments can drain the gallbladder to treat inflammation without surgery. However, after successful drainage, doctors currently do not know whether it is better to leave a stent inside for long-term drainage or to actively remove the gallbladder stones using an endoscope.\n\nThis multicenter study will follow patients in a real-world setting to compare these two approaches: the endoscopic treatment group (stone removal after drainage) and the non-endoscopic treatment group (long-term drainage alone). The goal is to evaluate which method is safer and more effective over the long term, helping doctors make better clinical decisions and improve patients' quality of life.",[25,26,27],"Gallbladder Diseases","Cholecystitis, Acute","Cholelithiasis",[29,30,31,32,33,34],"EUS-GBD","ET-GBD","PT-GBD","Gallbladder Preservation","High Surgical Risk","Endoscopic Drainage","NOT_YET_RECRUITING","2026-06-11",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Air Force Military Medical University, China","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":22,"phases":4,"briefSummary":61,"conditions":62,"keywords":74,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":47},"100540310","seattle-spatial-transcriptomic-research-in-inflammatory-bowel-disease-evaluation-stride-100540310","NCT06315179","Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)","Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation","STRIDE","Inclusion Criteria:\n\n* Suspected diagnosis of CD (Crohn's Disease), UC (Ulcerative Colitis) or Indeterminate colitis (IC)\n\nExclusion Criteria:\n\n* Evidence of Other Complicating Medical Issues:\n* Other serious medical conditions, such as neurological, liver, kidney, or systemic disease\n* Pregnancy\n* Tobacco, alcohol, or illicit drug abuse","6 Years","21 Years",{"count":59,"type":21},200,"3 Years","This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.",[63,64,65,66,67,68,69,70,71,25,72,73],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis","Indeterminate Colitis","Functional Abdominal Pain Syndrome","Functional Bowel Disorder","Esophageal Diseases","Gastroduodenal Disorder","Bowel Dysfunction","Sphincter of Oddi Dysfunction","Anorectal Disorder",[75,76],"IBD","DGBI","RECRUITING","2026-04-21",{"date":80,"type":39},"2026-04-24",{"date":82,"type":39},"2024-05-10",{"date":84,"type":21},"2030-01",{"name":86,"class":46},"Seattle Children's Hospital",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100627762","impact-of-pringle-maneuver-on-postoperative-gallbladder-diseases-after-hepatectomy-100627762","NCT07452848","Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy","Impact of Pringle Maneuver on the Occurrence of Postoperative Gallbladder Diseases After Hepatectomy: A Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n* Aged 18 to 85 years.\n* Definitive diagnosis of hepatic solid lesions confirmed by imaging (such as CT, MRI, or ultrasound) and\u002For pathology.\n* Underwent elective hepatectomy with gallbladder preservation.\n* Preoperative liver function evaluated as Child-Pugh class A or B.\n* Preoperative American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n\nExclusion Criteria:\n\n* Preoperative evaluation indicating pre-existing biliary tract diseases (e.g., cholelithiasis, biliary inflammation, neoplastic lesions).\n* History of previous upper abdominal surgery.\n* Application of non-hepatic inflow occlusion methods during surgery (e.g., hemihepatic vascular occlusion, selective segmental vascular occlusion).\n* Personal history of long-term use of hormone replacement therapy, somatostatin and its analogues, or oral contraceptives.\n* Loss to follow-up or missing critical data postoperatively.","85 Years",{"count":96,"type":21},2000,"The liver is an organ with a rich blood supply. During liver surgery (hepatectomy), surgeons often temporarily clamp the blood vessels supplying the liver to maintain a clear surgical field and reduce bleeding. This common technique is known as the Pringle maneuver. However, this maneuver also temporarily cuts off the blood supply to the gallbladder. Currently, doctors debate whether to routinely remove a healthy gallbladder during liver surgery to prevent future gallbladder problems, or to preserve it.\n\nThe primary purpose of this multicenter retrospective cohort study is to evaluate whether using the Pringle maneuver during liver surgery increases the risk of patients developing gallbladder diseases (such as gallstones or inflammation) later on. Researchers will review the past medical records of patients who underwent liver surgery with their gallbladder preserved between January 2012 and January 2022. By comparing patients who had the Pringle maneuver with those who did not, the study aims to provide reliable clinical evidence to help surgeons make better decisions about whether to preserve or remove the gallbladder during liver surgery.",[25,27],[100,101,102],"Pringle maneuver","Hepatectomy","Hepatic inflow occlusion","2026-03-01",{"date":105,"type":39},"2026-03-05",{"date":103,"type":21},{"date":108,"type":21},"2026-08",{"name":110,"class":46},"West China Hospital",8,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":119,"studyType":22,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100627170","research-on-construction-and-verification-of-multimodal-medical-imaging-large-model-100627170","NCT07445152","Research on Construction and Verification of Multimodal Medical Imaging Large Model","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years.\n* Patients who underwent imaging examinations (CT, MRI, ultrasound, etc.) at this hospital during the study period.\n* The examination items are consistent with the disease types or systems focused on by the study (hepatobiliary and pancreatic system).\n* Possess at least complete imaging data, radiological diagnostic reports, with relevant medical record information as supplementary modalities.\n* Patients and their legal representatives have signed an informed consent form, agreeing to the use of their de-identified data for scientific research model validation.\n\nExclusion Criteria:\n\n* Patients who refuse to sign the informed consent form.\n* Cases with unassessable images due to severe motion artifacts, incomplete scanning, or equipment abnormalities.\n* Cases with severe deficiency of clinical data or failure to match with imaging data.\n* Cases with special pathological conditions or post-operative status (e.g., extensive resection, significant structural changes after radiotherapy) that affect the consistency of model analysis.\n* Data samples with privacy protection or legal risks.",{"count":96,"type":21},"4 Weeks","With the accumulation of multimodal clinical data such as medical imaging and electronic health records (EHRs), efficient utilization of multi-source information to achieve precise diagnosis and intelligent decision-making has become a core direction of medical artificial intelligence (AI). Although traditional unimodal algorithms have yielded outcomes in specific tasks, their inability to model the semantic correlations among imaging, textual, and laboratory data leads to insufficient stability and limited interpretability of diagnostic results, making it difficult to meet the needs of comprehensive decision-making in complex clinical scenarios.\n\nIn recent years, multimodal large models have demonstrated excellent cross-modal understanding and knowledge transfer capabilities in natural images and general vision-language tasks, providing a new paradigm for medical AI. However, direct application in medical scenarios still faces challenges: first, the medical semantic system differs significantly from general language models, hindering the accurate representation of disease characteristics and imaging details; second, the complex morphology of lesions and uneven sample distribution in medical data increase the difficulty of model generalization; third, clinical data involves privacy, so data security and ethical compliance serve as prerequisites for research.\n\nThe research on medical multimodal large models aims to integrate multi-source heterogeneous medical data, establish a unified semantic representation and reasoning mechanism, and realize full-process intelligent analysis including disease identification and lesion localization. This approach can not only improve the efficiency and accuracy of clinical diagnosis but also provide clinicians with interpretable and traceable auxiliary decision support, boasting broad application prospects.\n\nBased on the hospital's clinical data resources and the research team's algorithmic foundation, this study intends to construct a multimodal large model system for medical imaging diagnosis, enabling closed-loop intelligent analysis from multimodal information fusion to diagnostic report generation. The research will strictly adhere to medical ethical standards, protect patients' right to information, right to privacy, and data security. Before the official launch of the project, ethical review must be passed, and relevant regulations shall be followed to ensure the unity of scientific research and ethics, laying a compliant foundation for subsequent clinical validation and promotion.",[122,25,123,124],"Liver Diseases","Pancreatic Diseases","Artificial Intelligence (AI)","2026-02-26",{"date":127,"type":39},"2026-03-03",{"date":129,"type":21},"2026-11-15",{"date":131,"type":21},"2027-11-15",{"name":133,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":22,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100344297","multicenter-prospective-cohort-study-of-risk-factors-for-gallbladder-cancer-100344297","NCT03762837","Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer","Inclusion Criteria:\n\n* Subjects who met the following four criteria entered the study.\n\n  1. A benign gallbladder disease is detected during a medical examination or visit (according to any imaging test);\n  2. healthy people without gallbladder disease;\n  3. Age greater than 18 years and less than 80 years old;\n  4. Sign the informed consent form. PS: If someone meets the condition (1) or (2), then he can be enrolled.\n\nExclusion Criteria:\n\n* Subjects can not enter the study by combining any of the following\n\n  1. Concomitant diseases such as severe mental illness, severe heart, lung and kidney;\n  2. Refusal of follow-up requirements.",true,{"count":142,"type":21},100000,"10 Years","This trial is a prospective study, the main purpose of the study is to investigate the association between benign gallbladder disease and gallbladder carcinoma; to explain the timing of intervention, intervention and early prevention of benign gallbladder disease; according to the national epidemiology of gallbladder cancer Center Clinical Research (unpublished), 2000 National Cholecystoma Clinical Epidemiology Report, and 2005 Clinical Analysis of 2379 Cases of Gallbladder Carcinoma in 17 Hospitals in Five Northwest Provinces, Pre-experimental data, using samples The volume estimation formula, α = 0.05, β = 0.1, plans to enroll 100,000 people.Half of participants is someone with Biliary benign disease，while the other half is healthy.",[25,146],"Healthy",[148],"Gallbladder cancer","2019-02-28",{"date":151,"type":39},"2019-03-04",{"date":153,"type":21},"2019-04-01",{"date":155,"type":21},"2029-12-31",{"name":157,"class":46},"Tongji Hospital"]